Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Opioid Receptor Antibodies

Opioid receptors are activated by a variety of endogenous peptides including enkephalins, β-endorphin, dynorphins or nociceptin/orphanin FQ (N/OFQ) that mediate primarily inhibitory functions in the central and peripheral nervous system. The opioid receptor family consists of four members designated μ-opioid receptor (mu-opioid receptor, MOP), δ-opioid receptor (delta-opioid receptor, DOP), κ-opioid receptor (kappa-opioid receptor, KOP), N/OFQ receptor (NOP). All four opioid receptors can mediate analgesic effects, which are accompanied by receptor-specific side effects. MOP is the pharmacological target for many clinically-used analgesics including morphine, oxycodone, fentanyl and methadone. The utility of µ-analgesics is limited by sever side effects such as respiratory depression, constipation and addiction. Specific side-effects induced by DOP, KOP and NOP include seizures, dysphoria and sedation, respectively. One strategy for the development of safer analgesics with fewer side effects is the development of drugs that target multiple opioid receptors. An alternative approach is the development of biased opioid analgesics.

Close filters
2 From 2
No results were found for the filter!
Citations
Agonist-induced Threonine363 phosphorylation of the κ-Opioid Receptor.
pT363-KOP (phospho-κ-Opioid Receptor Antibody)
Threonine363 is a major phosphorylation site of the kappa-opioid receptor (KOP). The pT363-KOP antibody detects phosphorylation in response to high-efficacy agonists. T363 phosphorylation is a key regulator of KOP desensitization,...
$ 375.00 *
Details
Citations
KO-Validated
MOP (non-phospho), µ-Opioid Receptor Antibody
MOP (non-phospho), µ-Opioid Receptor Antibody
The non-phospho-µ-opioid receptor antibody is directed against the distal end of the carboxyl-terminal tail of mouse, rat and human MOP. It detects selectively the canonical form of MOP and none of the putative splice variants. It can be...
$ 375.00 *
Details
Citations
Figure 1. Agonist-induced and Agonist-independent Serine363 phosphorylation of the µ-Opioid Receptor
pS363-MOP (phospho-µ-Opioid Receptor Antibody)
Serine363 (S363) is a constitutive phosphorylation site of the µ-opioid receptor (MOP). The pT363-MOP antibody detects phosphorylated MOP in cultured cells. S363 is a substrate for PKC-mediated phosphorylation.
$ 375.00 *
Details
2 From 2

For more information on opioid receptor pharmacology please refer to IUPHAR database. For further reading refer to:

Günther T, Dasgupta P, Mann A, Miess E, Kliewer A, Fritzwanker S, Steinborn R, Schulz S. Targeting multiple opioid receptors - improved analgesics with reduced side effects? Br J Pharmacol. 2018 Jul;175(14):2857-2868. doi: 10.1111/bph.13809. Epub 2017 May 26. Review. PubMed PMID: 28378462; PubMed Central PMCID: PMC6016677.

Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, Christie MJ. Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev. 2013 Jan 15;65(1):223-54. doi: 10.1124/pr.112.005942. Print 2013 Jan. Review. PubMed PMID: 23321159; PubMed Central PMCID: PMC3565916.

Gendron L, Cahill CM, von Zastrow M, Schiller PW, Pineyro G. Molecular Pharmacology of δ-Opioid Receptors. Pharmacol Rev. 2016 Jul;68(3):631-700. doi: 10.1124/pr.114.008979. Review. PubMed PMID: 27343248; PubMed Central PMCID: PMC4931872.

Toll L, Bruchas MR, Calo' G, Cox BM, Zaveri NT. Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems. Pharmacol Rev. 2016 Apr;68(2):419-57. doi: 10.1124/pr.114.009209. Epub 2016 Mar 8. Review. PubMed PMID: 26956246; PubMed Central PMCID: PMC4813427.

For more information on opioid receptor pharmacology please refer to IUPHAR database. For further reading refer to: Günther T, Dasgupta P, Mann A, Miess E, Kliewer A, Fritzwanker S, Steinborn... read more »
Close window
Opioid Receptor Antibodies

For more information on opioid receptor pharmacology please refer to IUPHAR database. For further reading refer to:

Günther T, Dasgupta P, Mann A, Miess E, Kliewer A, Fritzwanker S, Steinborn R, Schulz S. Targeting multiple opioid receptors - improved analgesics with reduced side effects? Br J Pharmacol. 2018 Jul;175(14):2857-2868. doi: 10.1111/bph.13809. Epub 2017 May 26. Review. PubMed PMID: 28378462; PubMed Central PMCID: PMC6016677.

Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, Christie MJ. Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev. 2013 Jan 15;65(1):223-54. doi: 10.1124/pr.112.005942. Print 2013 Jan. Review. PubMed PMID: 23321159; PubMed Central PMCID: PMC3565916.

Gendron L, Cahill CM, von Zastrow M, Schiller PW, Pineyro G. Molecular Pharmacology of δ-Opioid Receptors. Pharmacol Rev. 2016 Jul;68(3):631-700. doi: 10.1124/pr.114.008979. Review. PubMed PMID: 27343248; PubMed Central PMCID: PMC4931872.

Toll L, Bruchas MR, Calo' G, Cox BM, Zaveri NT. Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems. Pharmacol Rev. 2016 Apr;68(2):419-57. doi: 10.1124/pr.114.009209. Epub 2016 Mar 8. Review. PubMed PMID: 26956246; PubMed Central PMCID: PMC4813427.

Recently viewed